The buyer universe for American ophthalmology practices looks nothing like it did in 2021. Four years ago, any ophthalmologist deciding to sell had multiple competing bidders: private equity platforms backed by major sponsors (Partners Group at EyeCare Partners, Olympus Partners at EyeSouth, Gryphon at Vision Innovation, H.I.G. at American Vision Partners), strategic buyers evaluating the specialty, hospital systems actively employing specialists, and independent succession buyers in physician-led succession deals. Today, the buyer universe has narrowed dramatically. The contraction between 2023 and 2025 left a much smaller set of channels through which practices actually transact, and understanding who is buying American ophthalmology in 2026, and who isn't, is the starting point for understanding where the category goes next.

The Strategic Corporate Buyers at the Top

The biggest transactions in ophthalmology in the last eighteen months came from pharmaceutical distributors and healthcare strategic buyers, not from private equity. Cencora completed its acquisition of Retina Consultants of America on January 2, 2025 for $4.4 billion cash, with up to $500 million in earn-out payments tied to FY27-FY28 performance. The deal valued RCA at approximately 18.4x trailing EBITDA, brought 291 offices across 23 states with physician rollover equity representing roughly 15% of transaction value, and Cencora projected approximately $0.35 per share of accretion in year one. McKesson followed in April 2025 with its acquisition of PRISM Vision from Quad-C Management, an $850 million transaction covering 80% of PRISM that brought 200+ physicians, 91 offices, and 7 ambulatory surgery centers into the McKesson platform.

Cardinal Health, not to be left out of the specialty consolidation wave, acquired Solaris Health from Lee Equity in August 2025 for $1.9 billion. Solaris operates in urology rather than ophthalmology, but it fits the same specialty-distributor consolidation pattern that Cencora and McKesson are executing across specialties. Humana's CenterWell unit acquired MaxHealth from Arsenal Capital for approximately $1 billion in February 2025, bringing another 32,000+ patients under corporate payer ownership.

The pattern across these four transactions is direct. Pharmaceutical distributors and healthcare strategics are paying strategic multiples to acquire the trophy assets that private equity sponsors built over the last decade: Cencora at 18.4x EBITDA for RCA, McKesson paying strategic value for PRISM, Cardinal paying nearly $2 billion for Solaris urology. These aren't financial-buyer multiples; they're strategic-corporate multiples that reflect synergies with the buyer's existing distribution, specialty pharmacy, and value-based care infrastructure. What they have in common is that all of these deals required transactions at or above $800 million, because strategic corporate buyers at this scale don't transact below that threshold; their acquisition and integration cost structures don't work at smaller deal sizes. Cardinal's specialty platform serves 3,000+ providers across 32 states, and it isn't set up to acquire and integrate individual $2 million ophthalmology practices.

The PE Platforms That Aren't Buying

Between 2017 and 2019, more than a dozen PE-backed ophthalmology platforms formed with the explicit intent of consolidating the specialty: EyeCare Partners, EyeSouth Partners, Vision Innovation Partners, American Vision Partners, Unifeye Vision, Spectrum Vision Partners, US Eye, Eye Health America, and several others. Their 5-year fund lifecycles put the cohort into exit mode by 2023-2025, and most of them can't execute clean exits in the current environment. EyeCare Partners completed an out-of-court debt restructuring in April-May 2024 with Partners Group injecting new super-priority capital and maturities extended through 2027; it isn't acquiring new practices but trying to stabilize the platform it already built. Vision Innovation Partners is approaching its 27th add-on acquisition as of early 2026 but has no clean exit path, and continuing to add practices extends the hold period further.

American Vision Partners acquired eye-care services from Evernorth Care Group (Cigna) in August 2024, an unusual transaction where a vertically-integrated payer divested out, and AVP faces an ongoing whistleblower lawsuit (Dr. Charles Mayron, retina) filed in February 2025 alleging patient-safety issues that remains unresolved. Unifeye Vision Partners announced a new CEO in October 2025 (Mark Garvin replacing Martin Rash who became Executive Chair) and took growth capital from Morgan Stanley Private Credit and PGIM in May 2025; growth-capital financing at this stage of a PE platform lifecycle typically signals an inability to execute a clean exit. Eye Health America (LLR Partners) is still actively executing add-on acquisitions, including the February 2025 acquisition of Quigley Eye Specialists from New Harbor Capital, demonstrating that sponsor-to-sponsor add-ons continue to work at the mid-market level.

The pattern is consistent. PE platforms in ophthalmology are either trying to stabilize stuck positions, extending hold periods via add-ons, or taking growth capital instead of pursuing exits. None of the major platforms have reached the scale or balance-sheet strength to pursue aggressive acquisition strategies in 2026, and several are in forced-seller posture rather than buyer posture. New PE platform formation in healthcare has also slowed dramatically: H1 2025 healthcare specialist PE fundraising totaled $9.5 billion across 10 funds per PitchBook, but over half of that was a single fund (Linden VI). Excluding Linden VI, the entire healthcare specialist PE category raised $4.1 billion across 9 funds in six months, compared to 2023 peak fundraising of $21.7 billion or the 2021 peak of $18.3 billion. The fundraising collapse means that even if PE sponsors wanted to form new ophthalmology platforms, the capital to do so isn't flowing at historical rates, and new platform formation in 2026 and 2027 will be constrained by fund formation in 2024-2025, which was structurally weaker than prior cohorts.

The Hospitals That Won't Bid

American hospital systems are in retrenchment mode across physician employment generally, and ophthalmology specifically was never a hospital priority to begin with. Median hospital loss per employed physician reached $306,792 in Q4 2024 per Kaufman Hall, the first time the per-physician loss crossed $300,000, and at that loss rate hospital systems can't sustain expansion of physician employment without serious financial consequences. Ascension divested 12+ hospitals and affiliated practices across 2024-2025 in a multi-region strategic retrenchment. CommonSpirit reported an FY25 operating loss of $225 million (-0.6% margin) and consolidated its 8-region structure down to 5. Providence consolidated 7 divisions into 3. These are the largest Catholic and nonprofit hospital systems in America, and they aren't the exceptions but the pattern. Hospital operating margin median ran at 1.3% across the calendar-year-to-date December 2025 reporting period, and at those margins hospital systems can't absorb the sustained per-physician losses required to build specialty physician networks.

Ophthalmology was never a hospital-growth priority in the way that primary care or cardiology became in prior waves. The American Academy of Ophthalmology's own analysis of hospital employment trends in ophthalmology consistently noted that "ophthalmologists don't put many patients in hospital beds." The specialty generates most of its revenue outpatient and ambulatory, with ASC economics rather than hospital inpatient economics, and that structural mismatch means hospitals have historically not competed aggressively for ophthalmology practices. The current retrenchment environment makes it even less likely they'll start now. Add the per-physician loss to ophthalmology's structurally lower fit with hospital economics, and hospital employment is effectively eliminated as a buyer class for the remaining independent ophthalmology practices.

The Long Tail That Nobody's Absorbing

What's left after strategic corporates take the top, PE platforms can't buy, and hospitals retrench? Approximately 4,300 solo ophthalmologists are expected to exit practice through retirement or transition by 2030 based on AMA demographic data and American Academy of Ophthalmology workforce projections. Most of those practices generate annual revenue between $1-4 million, and almost all are below the $10 million threshold that strategic corporate buyers operate above.

Dental DSO data provides a useful reference point. The dental specialty saw DSOs capture 7.2% of US dental practices in 2015, rising to 16.1% by 2024, projected to 39% by 2026 per L.E.K. Consulting. Veterinary consolidation is further along, with approximately 50% of veterinary revenue flowing through corporate ownership structures, where specialty veterinary practices trade at 15-20x EBITDA and general-practice veterinary clinics trade at 8-12x. Ophthalmology's remaining solo practice base is structurally similar to dental general practice or veterinary general practice circa 2012-2015: cash-flowing businesses, demographic tailwinds, fragmented ownership, sub-$10 million average transaction size, physician operators approaching retirement.

What absorbed dental and vet at that stage wasn't strategic corporate buyers (who came later), wasn't hospital systems (which don't operate in those specialties), and wasn't new PE platform formation alone (though PE did participate). It was a combination of PE consolidators, operator-backed platforms, and patient-capital operators who understood that the underlying cash flow economics compounded reliably even when the headline growth profile didn't match institutional fund requirements. That's the capital class structurally positioned to absorb the long tail of ophthalmology practice succession: patient-capital operators running permanent-hold platforms that don't require 5-year exit cycles, don't require 18x EBITDA strategic multiples to justify transactions, and don't require minimum $800 million deal thresholds to operate. Sub-$10 million transactions, acquired individually, held indefinitely, compounding cash flow across decades.

The Arithmetic of 2026

Four buyer classes existed at the 2021 peak, and three are now eliminated or constrained. Strategic corporate buyers at the top tier are active, but only above $800 million transaction sizes, with approximately 10-15 practices per year potentially in scope at that scale. PE platforms in ophthalmology are mostly in stabilization, forced-seller, or limited-growth mode, with new platform formation constrained by fund formation collapse. Hospital systems are retrenching across physician employment broadly, and ophthalmology was never a priority, which leaves it effectively eliminated as a buyer. Independent succession and patient-capital operators remain the only structurally viable buyer class for the practices below the strategic corporate threshold. In 2021, American ophthalmology had all four buyer classes actively competing; in 2026, only one remains functionally operational across the sub-$10 million transaction segment where most of the category's remaining opportunity sits. That's a market restructuring, not a market slowdown, and the capital that understands the new buyer topology is positioned to absorb what the old topology left behind.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com